Synthetic Biologics, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven Shallcross
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9605 Medical Center Dr Ste 270 Rockville MD United States of America 20850
- IPO Date
- Feb 12, 1993
- CIK
- 0000894158
- Website
- syntheticbiologics.com
- Similar Companies
- Business
- Synthetic Biologics, Inc., rebranded as Theriva Biologics, Inc. in October 2022, is a clinical-stage pharmaceutical company specializing in immuno-oncology therapeutics primarily focused on developing novel oncolytic viruses for the treatment of difficult-to-treat solid tumors. The company’s core products include VCN-01, a systemically administered oncolytic adenovirus designed to break down the protective stroma barrier surrounding tumors to enhance the efficacy of co-administered cancer therapies and stimulate a robust immune response; VCN-11, another oncolytic virus leveraging proprietary Albumin Shield Technology to protect viruses from immune system neutralization; SYN-004 (ribaxamase), an oral enzyme therapeutic intended to degrade IV beta-lactam antibiotics in the gastrointestinal tract to protect the microbiome during antibiotic treatment; and SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase (IAP) aimed at treating GI and systemic diseases. Theriva operates its clinical and preclinical development programs primarily in the United States and Spain, with headquarters in Rockville, Maryland. Recent major company developments include the strategic acquisition of VCN Biosciences, S.L., which advanced Theriva’s position in oncolytic virus therapies with its innovative adenovirus platform suitable for intravenous and intravitreal delivery. The acquisition and rebranding reflected a strategic pivot and sharpened focus on oncolytic virus technology for cancer treatment. The company has reported promising clinical data in its VIRAGE Phase 2b trial evaluating VCN-01 in combination with chemotherapy for pancreatic cancer, positioning it for a potential Phase 3 study. Theriva continues to advance its pipeline and is actively exploring synergistic combinations with chemotherapies and immuno-oncology agents to expand its therapeutic offerings. The company’s strategic growth is marked by efforts to enhance systemic delivery of oncolytic viruses and to develop therapies with differentiated mechanisms that overcome the limitations of traditional approaches. Theriva Biologics operates within the biotechnology and pharmaceutical industry, targeting hard-to-treat oncology indications alongside potential microbiome-protective therapeutics in infectious diseases and inflammatory disorders. The company’s business segments focus on therapeutic development with a significant emphasis on immuno-oncology and microbiome preservation. Since its founding in 2012 and headquarters establishment in Maryland, Theriva has evolved through acquisitions and pipeline expansion to a specialized clinical-stage company. Its strategic focus includes leveraging proprietary and acquired technology platforms to address areas of high unmet medical need through novel biologics and viral therapeutics. The company engages in collaborations with academic and pharmaceutical entities to enhance its research and development efforts, maintaining a presence in North America and Europe. Theriva’s differentiated product candidates are designed to provide systemic delivery, enhance tumor accessibility, promote immune activation, and reduce adverse effects associated with current standard therapies. The company's emphasis on delivering a new class of oncolytic therapeutics underscores its innovation-driven approach to cancer treatment and related disease areas. Theriva Biologics continues to focus on clinical advancement and expansion of its pipeline with targeted therapies that emphasize systemic administration capability, tumor microenvironment modification, and microbiome protection, representing its latest major strategic and operational evolution in 2024 and 2025.
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript)
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q1 2022 Results - Earnings Call Transcript
Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results
5 Top Biotech Penny Stocks Under $1 To Watch This Week
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call Transcript
Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results
Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference
Synthetic Biologics, Inc.'s (SYN) CEO Steven Shallcross on Q3 2021 Results - Earnings Call Transcript
5 Top Penny Stocks To Buy For Under $5 On Webull Today
Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021
Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2021 Results - Earnings Call Transcript
Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital
Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021
3 Biotech Penny Stocks That You Need to Know About In 2021